Wealthcare Advisory Partners LLC Has $2.64 Million Stock Position in Astera Labs, Inc. $ALAB

Wealthcare Advisory Partners LLC raised its position in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 0.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,160 shares of the company’s stock after acquiring an additional 221 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Astera Labs were worth $2,637,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fred Alger Management LLC lifted its holdings in Astera Labs by 13.0% during the 1st quarter. Fred Alger Management LLC now owns 1,560,033 shares of the company’s stock worth $93,087,000 after purchasing an additional 179,638 shares during the last quarter. Hoey Investments Inc. increased its position in Astera Labs by 22.4% during the 2nd quarter. Hoey Investments Inc. now owns 6,121 shares of the company’s stock worth $553,000 after buying an additional 1,121 shares during the period. Wealth Effects LLC acquired a new stake in shares of Astera Labs during the second quarter worth $242,000. Sheets Smith Wealth Management bought a new stake in shares of Astera Labs in the second quarter valued at about $481,000. Finally, Aigen Investment Management LP boosted its position in shares of Astera Labs by 50.9% in the first quarter. Aigen Investment Management LP now owns 17,920 shares of the company’s stock valued at $1,069,000 after acquiring an additional 6,045 shares during the period. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other Astera Labs news, General Counsel Philip Mazzara sold 10,000 shares of the stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $192.16, for a total transaction of $1,921,600.00. Following the completion of the sale, the general counsel owned 151,573 shares of the company’s stock, valued at approximately $29,126,267.68. This represents a 6.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jack R. Lazar sold 22,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 27th. The stock was sold at an average price of $178.42, for a total transaction of $4,014,450.00. Following the transaction, the director owned 97,351 shares of the company’s stock, valued at approximately $17,369,365.42. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,492,036 shares of company stock worth $232,607,552. 12.50% of the stock is currently owned by insiders.

Astera Labs Price Performance

ALAB opened at $220.81 on Tuesday. Astera Labs, Inc. has a fifty-two week low of $47.13 and a fifty-two week high of $262.90. The company’s 50 day moving average price is $191.76 and its two-hundred day moving average price is $120.89. The firm has a market capitalization of $36.70 billion, a price-to-earnings ratio of 394.30, a PEG ratio of 5.09 and a beta of 1.43.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.11. The company had revenue of $191.93 million for the quarter, compared to analyst estimates of $172.46 million. Astera Labs had a net margin of 16.54% and a return on equity of 9.53%. Astera Labs’s revenue was up 149.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.13 earnings per share. Astera Labs has set its Q3 2025 guidance at 0.380-0.390 EPS. As a group, equities research analysts predict that Astera Labs, Inc. will post 0.34 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ALAB shares. Wall Street Zen lowered shares of Astera Labs from a “buy” rating to a “hold” rating in a research report on Friday. Northland Capmk cut shares of Astera Labs from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 22nd. TD Cowen assumed coverage on Astera Labs in a report on Wednesday, October 1st. They set a “hold” rating and a $200.00 price target for the company. Barclays restated an “overweight” rating and set a $155.00 price objective (up from $75.00) on shares of Astera Labs in a research report on Thursday, August 7th. Finally, Citigroup lifted their target price on Astera Labs from $160.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $159.83.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.